Specific clpp protease inhibitors for bacterial and cancer cell targeting
Innovative ClpP protease inhibitors capable of selectively targeting bacteria and cancer cells, particularly AML cells. This research aims to develop specific inhibitors with potential applications in treating infectious diseases and cancer.
Overview
The research focuses on developing selective inhibitors for the ClpP protease, a crucial enzyme present in bacteria and mammalian mitochondria. ClpP protease is pivotal in bacterial infectivity and cancer cell viability, specifically acute myeloid leukemia (AML) cells. By targeting and inhibiting ClpP, this solution offers a novel method to combat bacterial infections and certain cancer types, potentially revolutionizing treatment strategies.
Technical specifications
Key features:
- Selective inhibition: Targets ClpP protease in bacteria like Neisseria meningitidis and in AML cancer cells.
- Broad application: Potentially applicable for treating infectious diseases and cancer.
- Assay validation: Utilizes established assays to test efficacy on both bacterial and cancer cell lines.
- Future testing: Includes plans for animal studies to further validate efficacy and safety.
Technology readiness level
This research is at Technology Readiness Level 4, indicating that the technology has been validated in a laboratory setting. Future steps include testing in animal models to ensure effectiveness and safety in more complex biological systems.
About University of Toronto
The University of Toronto is a comprehensive public research university with three campuses in the Toronto region and a globally scaled research enterprise. Its downtown footprint is embedded within a major academic health network and an adjacent innovation district, enabling co-located labs, clinical trials, and rapid testing with end users. Companies connect through co-op and long-duration internships, sponsored research, and access to shared core facilities and prototyping resources. Research is supported by Canada’s Tri‑Agency (NSERC, CIHR, SSHRC) and the Canada Foundation for Innovation, alongside provincial programs and industry partnerships. A dedicated technology transfer office provides IP management, licensing, and startup support through a coordinated entrepreneurship network.
delivered to your inbox.